Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505085

2023-01-01

Abstract:Figure S4 shows the long-term role of anti-MET VHH pool in treating mice.

What problem does this paper attempt to address?

Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505088.v1

2023-01-01

Abstract:Figure S3 shows the efficacy of anti-MET VHH pool on tumor growth in individual mouse.
Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505091

2023-01-01

Abstract:Figure S2 shows the specificity of anti-MET VHH pool on MET in killing cancer cells.
Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Zhipeng Su,Yunchun Han,Qichen Sun,Xiaoxiao Wang,Ting Xu,Wei Xie,Xing Huang

DOI: https://doi.org/10.1158/1535-7163.22505076

2023-01-01

Abstract:Figure S7 shows the model of anti-MET VHH pool overcoming MET-targeted cancer therapeutic resistance.
Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Hang-Ping Yao,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1016/j.drudis.2020.11.002

IF: 8.369

2021-01-01

Drug Discovery Today

Abstract:•Cancerous MET overexpression is a common pathological feature manifested by genetic, molecular, and cellular abnormalities.•Conventional therapeutic antibodies targeting MET, under clinical trials for almost 10 years, have made little progress with various setbacks.•Novel biotherapeutics, such as bispecific antibodies, antibody-drug conjugates, and their combination, are under anti-MET clinical trials.•Amivantamab, a MET/EGFR bispecific antibody, has been granted the Breakthrough Therapy Designation status for treatment of advanced NSCLC.•An emerging era of antibody-based biotherapeutics for treatment of cancer overexpressing MET is in the horizon.
MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

Jian-Ya Zhou,Xi Chen,Jing Zhao,Zhang Bao,Xing Chen,Pei Zhang,Zhen-Feng Liu,Jian-Ying Zhou

DOI: https://doi.org/10.1016/j.canlet.2014.06.010

IF: 9.756

2014-01-01

Cancer Letters

Abstract:In non-small-cell lung cancer (NSCLC) that harbours an activating epidermal growth factor receptor (EGFR) mutation, over-expression of hepatocyte growth factor (HGF) is an important mechanism involved in the acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs) by restoring activity of the PI3K/Akt pathway via phosphorylation of MET. In our study, we found that the forced expression of miR-34a inhibited cell growth and induced apoptosis partly by targeting MET in HGF-induced gefitinib-resistant HCC827 and PC-9 cells. Furthermore, dramatic tumour regression was observed in the miR-34a plus gefitinib group in HGF-induced gefitinib resistant mouse xenograft models. This study demonstrates for the first time that miR-34a rescues HGF-induced gefitinib resistance in EGFR mutant NSCLC cells.
Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Xiangheng Chen,Zhonghai Guan,Jun Lu,Haohao Wang,Zhongkun Zuo,Fei Ye,Jiangsheng Huang,Lisong Teng

DOI: https://doi.org/10.7150/jca.20964

IF: 3.9

2018-01-01

Journal of Cancer

Abstract:cMet signaling pathway is involved in the resistance to anti-VEGF therapy and cMet overexpression is associated with tumor progression and poor prognosis. In this study, the expression of cMet in 146 Chinese colorectal cancer (CRC) patients was examined by immunohistochemistry staining. Our data demonstrated that cMet overexpression rate was 42.5% (62/146) and cMet overexpression was closely correlated with distant metastasis of CRC. Using CRC patient-derived xenograft (PDX) mouse models we investigated antitumor activity of a novel selective cMet inhibitor volitinib alone or in combination with anti-VEGF inhibitor apatinib in vivo. Our results showed that combination treatment significantly inhibited tumor growth in two PDX models. While volitinib treatment alone induced moderate improvement in tumor growth inhibition, combination treatment synergistically reduced microvessel density, suppressed proliferation, and increased apoptosis in PDX models. Further analysis showed synergistic inhibition of MAPK and PI3K/Akt pathways by volitinib and apatinib. Taken together, our data provide a rationale to targeting both cMet and VEGF in the treatment of cMet overexpressing CRC in clinical trials.
Abstract LB-015: Differential Therapeutic Responses of MET Oncogenic Activations to Met Kinase Inhibitor and Neutralizing Antibody

Jianqun Kou,Ben Staal,Phillip R. Musich,Liang Kang,Yuan Qin,Zhi Q. Yao,Boheng Zhang,Tam Angela,Alan Huang,Huaixiang Hao,George F. Vande Woude,Qian Xie

DOI: https://doi.org/10.1158/1538-7445.am2018-lb-015

IF: 11.2

2018-01-01

Cancer Research

Abstract:Abstract Purpose: MET inhibitors are in clinical trials against several cancer types, but the mechanisms toward vulnerability remain elusive. Here we characterized the molecular basis of MET amplification (METamp) and HGF-autocrine driven tumors in response to MET tyrosine kinase inhibitors (TKI) and neutralizing antibodies. Experimental Design: METamp (MKN45 and MHCC97H) and HGF-autocrine activation (JHH5 and U87) cells were treated by the MET kinase inhibitor (INC280) and the anti-MET monoclonal antibody (MetMab) to determine the sensitivity and biological responses in vitro. Tumor inhibition was evaluated in vivo using SCID and SCIDhgf mouse models, respectively. HGF-mediated angiogenesis was measured by using the human endothelial cells (HUVEC) tube formation assay. Results: MKN45 and MHCC97H cells are more sensitive than JHH5 and U87 cells to INC280 treatment but are unresponsive to MetMab. In METamp cells, INC280 induced a DNA damage response with activation of repair through the p53BP1/ATM signaling pathway. Although INC280 and MetMab showed a moderate inhibitory effect on - JHH5 and U87 cells in vitro, both treatments potently suppressed tumor growth in mouse models. We found that HGF stimulation promotes human HUVEC cell tube formation via the Src pathway. INC280 or MetMab inhibited tube formation; thus in HGF-autocrine tumors, the endothelial cells are the secondary targets of tumor-derived HGF and MET inhibition. Conclusion: METamp and HGF-autocrine activation favor different molecular mechanisms, such as a DNA damage response or angiogenesis. Because individual types of MET oncogenic activation may respond to MET inhibitors differently, combination strategies should be developed based upon the molecular subtypes of the tumors. Citation Format: Jianqun Kou, Ben Staal, Phillip R. Musich, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Tam Angela, Alan Huang, Huaixiang Hao, George F. Vande Woude, Qian Xie. Differential therapeutic responses of MET oncogenic activations to Met kinase inhibitor and neutralizing antibody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-015.
Supplemental Figure 4 Dose-dependent Inhibition from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Anna Li,Jing Yang,Xuchao Zhang,Zhou Zhang,Jian Su,Lan-ying Gou,Y. Bai,Qing Zhou,Zhenfan Yang,Han,Wen‐Zhao Zhong,Shannon Chuai,Qi Zhang,Zhi Xie,Hongfei Gao,Huajun Chen,Zhen Wang,Zheng Wang,Xue‐Ning Yang,Bin-Chao Wang,Bin Gan,Zhihong Chen,Ben‐Yuan Jiang,Si-Pei Wu,Siyang Liu,Chong‐Rui Xu,Yi‐Long Wu

DOI: https://doi.org/10.1158/1078-0432.22463061.v1

2023-01-01

Abstract:A-B. Female nu/nu athymic nude mice bearing MET mY1228H (A) and MET mY1226N (B) were treated with increasing dose of XL184 at 0mg/kg/d, 5mg/kg/d, 20mg/kg/d or 60mg/kg/d. Dose-dependent inhibition was observed for both mutations (Non-linear mixed effect model, p<0.0001).
Supplementary Figure 3 from C-Myc Alterations Confer Therapeutic Response and Acquired Resistance to C-Met Inhibitors in MET-Addicted Cancers

Aijun Shen,Lu Wang,Min Huang,Jingya Sun,Yi Chen,Yan-Yan Shen,Xinying Yang,Xin Wang,Jian Ding,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22405343

2023-01-01

Abstract:Supplementary Figure 3-c-Myc determines clinical response and resistance for c-Met targeted therapy.
Supplementary Figure S6 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Stephen J. Blake,Kimberley Stannard,Jing Liu,Stacey Allen,Michelle C.R. Yong,Deepak Mittal,Amelia Roman Aguilera,John J. Miles,Viviana P. Lutzky,Lucas Ferrari de Andrade,Ludovic Martinet,Marco Colonna,Kazuyoshi Takeda,Florian Kühnel,Engin Gürlevik,Günter Bernhardt,Michele W.L. Teng,Mark J. Smyth

DOI: https://doi.org/10.1158/2159-8290.22531002.v1

2023-01-01

Abstract:Supplementary Figure S6. Anti-CD96 combines with anti-CTLA4, anti-PD1 or doxorubicin to increase survival and reduce metastases in mice bearing 4T1.2 spontaneous metastases.
Differential Responses of MET Activations to MET Kinase Inhibitor and Neutralizing Antibody.

Jianqun Kou,Phillip R. Musich,Ben Staal,Liang Kang,Yuan Qin,Zhi Q. Yao,Boheng Zhang,Weizhong Wu,Angela Tam,Alan Huang,Huai-Xiang Hao,George F. Vande Woude,Qian Xie

DOI: https://doi.org/10.1186/s12967-018-1628-y

IF: 8.44

2018-01-01

Journal of Translational Medicine

Abstract:BACKGROUND:Aberrant MET tyrosine kinase signaling is known to cause cancer initiation and progression. While MET inhibitors are in clinical trials against several cancer types, the clinical efficacies are controversial and the molecular mechanisms toward sensitivity remain elusive.METHODS:With the goal to investigate the molecular basis of MET amplification (METamp) and hepatocyte growth factor (HGF) autocrine-driven tumors in response to MET tyrosine kinase inhibitors (TKI) and neutralizing antibodies, we compared cancer cells harboring METamp (MKN45 and MHCCH97H) or HGF-autocrine (JHH5 and U87) for their sensitivity and downstream biological responses to a MET-TKI (INC280) and an anti-MET monoclonal antibody (MetMab) in vitro, and for tumor inhibition in vivo.RESULTS:We find that cancer cells driven by METamp are more sensitive to INC280 than are those driven by HGF-autocrine activation. In METamp cells, INC280 induced a DNA damage response with activation of repair through the p53BP1/ATM signaling pathway. Although MetMab failed to inhibit METamp cell proliferation and tumor growth, both INC280 and MetMab reduced HGF-autocrine tumor growth. In addition, we also show that HGF stimulation promoted human HUVEC cell tube formation via the Src pathway, which was inhibited by either INC280 or MetMab. These observations suggest that in HGF-autocrine tumors, the endothelial cells are the secondary targets MET inhibitors.CONCLUSIONS:Our results demonstrate that METamp and HGF-autocrine activation favor different molecular mechanisms. While combining MET TKIs and ATM inhibitors may enhance the efficacy for treating tumors harboring METamp, a combined inhibition of MET and angiogenesis pathways may improve the therapeutic efficacy against HGF-autocrine tumors.
Supplementary Figure S1 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Zheng Zhang,Yang Zhang,Qian Sun,Fei Feng,Muren Huhe,Li Mi,Zhinan Chen

DOI: https://doi.org/10.1158/1535-7163.22501722

2023-01-01

Abstract:Supplementary Figure S1. Images of anti-tumor efficacy of Metuzumab in SCID mice bearing A549 (left) and NCI-H520 (right) human lung cancer cell line xenografts.
Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Lu Xu,Eiki Kikuchi,Chunxiao Xu,Hiromichi Ebi,Dalia Ercan,Katherine A. Cheng,Robert Padera,Jeffrey A. Engelman,Pasi A. Jänne,Geoffrey I. Shapiro,Takeshi Shimamura,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22391819.v1

2023-01-01

Abstract:PDF file - 1.4MB, Supplemental Figure 1. MET is inducible in MET, TD/MET, and TL/MET models Supplemental Figure 2. Quantification of hMET expression in mouse models Supplemental Figure 3. Comparison of the tumor counts in mutant EGFR lung tumors with or without expression of hMET. Supplemental Figure 4. Representative MRI images prior to and after treatment in TL and TL/MET mice. Supplemental Figure 5. Xenografts of HCC827GR6 cells ectopically expressing EGFR E746_A750del/T790M are sensitive to the combination of WZ4002 and 17-DMAG. Supplemental Figure 6. The WZ4002/crizotinib or WZ4002/17-DMAG combinations suppress phosphorylation of EGFR, Akt, and Erk in TD and TD/MET to a greater extent than individual treatments
Supplementary Figure 1 from C-Myc Alterations Confer Therapeutic Response and Acquired Resistance to C-Met Inhibitors in MET-Addicted Cancers

Aijun Shen,Lu Wang,Min Huang,Jingya Sun,Yi Chen,Yan-Yan Shen,Xinying Yang,Xin Wang,Jian Ding,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22405352

2023-01-01

Abstract:Supplementary Figure 1-Multiple kinases are co-activated in c-Met-resistant cells.
Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models

John O. DaSilva,Katie Yang,Andrés E. Perez Bay,Julian Andreev,Peter Ngoi,Erica Pyles,Matthew C. Franklin,Drew Dudgeon,Ashique Rafique,Anthony J. Dore,Frank J. Delfino,Terra Potocky,Robert G. Babb,Gang Chen,Douglas MacDonald,William C. Olson,Gavin Thurston,Christopher Daly

DOI: https://doi.org/10.1158/1078-0432.22479116

2023-01-01

Abstract:Supplementary figure legends and methods
Supplementary Figure S1 from MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING

Yong Zhang,Qifan Yang,Xiangyu Zeng,Manxiang Wang,Shuang Dong,Bin Yang,Xinyi Tu,Ting Wei,Wenzhuan Xie,Chao Zhang,Qiang Guo,Jake A. Kloeber,Yunxia Cao,Guijie Guo,Qin Zhou,Fang Zhao,Jinzhou Huang,Li Liu,Kai Zhang,Mingwei Wang,Ping Yin,Kuntian Luo,Min Deng,Wootae Kim,Jing Hou,Shuang Yu,Qian Zhu,Lifeng Chen,Sheng Hu,Junqiu Yue,Guoliang Pi,Zhenkun Lou

DOI: https://doi.org/10.1158/2159-8290.22540859.v1

2023-01-01

Abstract:Case report of resistance to ICB in patients with MET amplification and MET is a biomarker and driver for ICB resistance
Supplementary Figure 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Hongkui Jin,Renhui Yang,Zhong Zheng,Mally Romero,Jed Ross,Hani Bou-Reslan,Richard A.D. Carano,Ian Kasman,Elaine Mai,Judy Young,Jiping Zha,Zemin Zhang,Sarajane Ross,Ralph Schwall,Gail Colbern,Mark Merchant

DOI: https://doi.org/10.1158/0008-5472.22373646.v1

2023-01-01

Abstract:Supplementary Figure 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
Supplementary Figure 3 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Hongkui Jin,Renhui Yang,Zhong Zheng,Mally Romero,Jed Ross,Hani Bou-Reslan,Richard A.D. Carano,Ian Kasman,Elaine Mai,Judy Young,Jiping Zha,Zemin Zhang,Sarajane Ross,Ralph Schwall,Gail Colbern,Mark Merchant

DOI: https://doi.org/10.1158/0008-5472.22373640.v1

2023-01-01

Abstract:Supplementary Figure 3 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
Data from Anti-MET ImmunoPET for Non–Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments

Keyu Li,Richard Tavare,Kirstin A. Zettlitz,Shannon M. Mumenthaler,Parag Mallick,Yu Zhou,James D. Marks,Anna M. Wu

DOI: https://doi.org/10.1158/1535-7163.mct-14-0363

2014-01-01

Molecular Cancer Therapeutics

Abstract:Abstract MET, the receptor of hepatocyte growth factor, plays important roles in tumorigenesis and drug resistance in numerous cancers, including non–small cell lung cancer (NSCLC). As increasing numbers of MET inhibitors are being developed for clinical applications, antibody fragment–based immunopositron emission tomography (immunoPET) has the potential to rapidly quantify in vivo MET expression levels for drug response evaluation and patient stratification for these targeted therapies. Here, fully human single-chain variable fragments (scFvs) isolated from a phage display library were reformatted into bivalent cys-diabodies (scFv-cys dimers) with affinities to MET ranging from 0.7 to 5.1 nmol/L. The candidate with the highest affinity, H2, was radiolabeled with 89Zr for immunoPET studies targeting NSCLC xenografts: low MET-expressing Hcc827 and the gefitinib-resistant Hcc827-GR6 with 4-fold MET overexpression. ImmunoPET at as early as 4 hours after injection produced high-contrast images, and ex vivo biodistribution analysis at 20 hours after injection showed about 2-fold difference in tracer uptake levels between the parental and resistant tumors (P < 0.01). Further immunoPET studies using a larger fragment, the H2 minibody (scFv-CH3 dimer), produced similar results at later time points. Two of the antibody clones (H2 and H5) showed in vitro growth inhibitory effects on MET-dependent gefitinib-resistant cell lines, whereas no effects were observed on resistant lines lacking MET activation. In conclusion, these fully human antibody fragments inhibit MET-dependent cancer cells and enable rapid immunoPET imaging to assess MET expression levels, showing potential for both therapeutic and diagnostic applications. Mol Cancer Ther; 13(11); 2607–17. ©2014 AACR.
Supplementary Figure 2 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Hongkui Jin,Renhui Yang,Zhong Zheng,Mally Romero,Jed Ross,Hani Bou-Reslan,Richard A.D. Carano,Ian Kasman,Elaine Mai,Judy Young,Jiping Zha,Zemin Zhang,Sarajane Ross,Ralph Schwall,Gail Colbern,Mark Merchant

DOI: https://doi.org/10.1158/0008-5472.22373643

2023-01-01

Abstract:Supplementary Figure 2 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Figure S4 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S3 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Figure S7 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Abstract LB-015: Differential Therapeutic Responses of MET Oncogenic Activations to Met Kinase Inhibitor and Neutralizing Antibody

Supplemental Figure 4 Dose-dependent Inhibition from Acquired &lt;i&gt;met&lt;/i&gt; Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplementary Figure 3 from C-Myc Alterations Confer Therapeutic Response and Acquired Resistance to C-Met Inhibitors in MET-Addicted Cancers

Supplementary Figure S6 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Differential Responses of MET Activations to MET Kinase Inhibitor and Neutralizing Antibody.

Supplementary Figure S1 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Figure 1 from C-Myc Alterations Confer Therapeutic Response and Acquired Resistance to C-Met Inhibitors in MET-Addicted Cancers

Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models

Supplementary Figure S1 from MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING

Supplementary Figure 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Supplementary Figure 3 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Data from Anti-MET ImmunoPET for Non–Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments

Supplementary Figure 2 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Supplemental Figure 4 Dose-dependent Inhibition from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer